image
Healthcare - Biotechnology - NASDAQ - GB
$ 0.8504
-0.869 %
$ 697
Market Cap
-0.06
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one BDRX stock under the worst case scenario is HIDDEN Compared to the current market price of 0.85 USD, Biodexa Pharmaceuticals Plc is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one BDRX stock under the base case scenario is HIDDEN Compared to the current market price of 0.85 USD, Biodexa Pharmaceuticals Plc is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one BDRX stock under the best case scenario is HIDDEN Compared to the current market price of 0.85 USD, Biodexa Pharmaceuticals Plc is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BDRX

image
$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.0$0.5$0.5Feb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 Jul
FINANCIALS
381 K REVENUE
-45.49%
-8.01 M OPERATING INCOME
10.28%
-5.73 M NET INCOME
19.07%
-12.3 M OPERATING CASH FLOW
-79.62%
-598 K INVESTING CASH FLOW
-125.66%
8.56 M FINANCING CASH FLOW
-16.32%
0 REVENUE
0.00%
-4.22 M OPERATING INCOME
-12.02%
-2.42 M NET INCOME
26.81%
-7.45 M OPERATING CASH FLOW
-55.07%
156 K INVESTING CASH FLOW
120.69%
3.91 M FINANCING CASH FLOW
-15.78%
Balance Sheet Biodexa Pharmaceuticals Plc
image
Current Assets 8.81 M
Cash & Short-Term Investments 1.67 M
Receivables 715 K
Other Current Assets 6.43 M
Non-Current Assets 5.97 M
Long-Term Investments 0
PP&E 324 K
Other Non-Current Assets 5.65 M
11.29 %4.84 %43.48 %38.20 %Total Assets$14.8m
Current Liabilities 5.03 M
Accounts Payable 707 K
Short-Term Debt 609 K
Other Current Liabilities 3.72 M
Non-Current Liabilities 1.42 M
Long-Term Debt 118 K
Other Non-Current Liabilities 1.31 M
10.95 %9.43 %57.57 %20.22 %Total Liabilities$6.5m
EFFICIENCY
Earnings Waterfall Biodexa Pharmaceuticals Plc
image
Revenue 381 K
Cost Of Revenue 4.07 M
Gross Profit -3.69 M
Operating Expenses 4.33 M
Operating Income -8.01 M
Other Expenses -2.28 M
Net Income -5.73 M
1m1m00(1m)(1m)(2m)(2m)(3m)(3m)(4m)(4m)(5m)(5m)(6m)(6m)(7m)(7m)(8m)(8m)(9m)(9m)381k(4m)(4m)(4m)(8m)2m(6m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
0.00% ROE
0.00%
0.00% ROA
0.00%
0.00% ROIC
0.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Biodexa Pharmaceuticals Plc
image
00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)(16m)(16m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -5.73 M
Depreciation & Amortization 254 K
Capital Expenditures -774 K
Stock-Based Compensation 283 K
Change in Working Capital -3.74 M
Others -844 K
Free Cash Flow -13 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Biodexa Pharmaceuticals Plc
image
BDRX has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Biodexa Pharmaceuticals Plc
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
ADR Ratio Change July 15, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces a ratio change on its American Depositary Receipts (“ADR”) from one (1) ADR representing ten thousand (10,000) ordinary shares, to the new ratio of one (1) ADR representing one hundred thousand (100,000) ordinary shares (the "Ratio Change"). The effective date of the Ratio Change is expected to be July 31, 2025. globenewswire.com - 1 week ago
Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) July 14, 2025 Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced the filing of a Clinical Trial Application (CTA) with the European Medicines Agency (EMA) for its Serenta trial in patients with familial adenomatous polyposis (FAP), a mostly inherited disease that, if left untreated, almost always leads to colorectal cancer. The only current treatment option is sequential resection of much of the gastrointestinal tract. globenewswire.com - 1 week ago
Results of Annual General Meeting June 27, 2023 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Results of Annual General Meeting Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces that at its Annual General Meeting held yesterday, all resolutions put to the Company's shareholders were duly passed. The full text of, inter alia, the resolutions proposed and passed at the Annual General Meeting can be found in the Notice of the Annual General Meeting on the Company's website at https://biodexapharma.com/investors/corporate-governance//#agms. globenewswire.com - 3 weeks ago
Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) June 25, 2025 Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce the activation of the first clinical study site for its Serenta trial in patients with familial adenomatous polyposis (FAP). The trial, which is now enrolling, represents a significant milestone in the development of a potential new treatment option for FAP. globenewswire.com - 3 weeks ago
Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) June 23, 2025 Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce it has selected Serenta as the brand name for its upcoming phase 3 clinical study in familial adenomatous polyposis (FAP). In conjunction with this announcement, the company launched a dedicated website, www.serentatrial.com, to provide information and resources for patients, caregivers, and healthcare professionals. globenewswire.com - 4 weeks ago
Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study CARDIFF, UNITED KINGDOM / ACCESS Newswire / June 18, 2025 / When it comes to type 1 diabetes, treating this chronic condition can be difficult. After all, with this type of diabetes, the body's immune system attacks and destroys the beta cells that produce insulin. accessnewswire.com - 1 month ago
Result of General Meeting June 11, 2025 Biodexa Pharmaceuticals PLC Result of General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces, announces that at its General Meeting held earlier today, all four resolutions put to the Company's shareholders were duly passed. The full text of, inter alia, the resolutions proposed and passed at the Annual General Meeting and General Meeting can be found in the Notice of the General Meeting on the Company's website at: https://biodexapharma.com/investors/corporate-governance/#agms. globenewswire.com - 1 month ago
Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes June 4, 2025 Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the recruitment of the first patient in a Phase 2 study of tolimidone in Type 1 Diabetes (“T1D”). The study is an Investigator Initiated Trial (IIT) conducted by the University of Alberta Diabetes Institute. globenewswire.com - 1 month ago
Shareholder Update May 30, 2025 Biodexa Pharmaceuticals PLC Shareholder Update Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced a brief update for shareholders. Financial position As of May 29, 2025, the Company had access to the following cash resources:     $ millions Cash at bank   5.7 Cash in escrow for eRapa Phase 3 program   4.4     10.1       Undrawn CPRIT grant for eRapa Phase 3 program   11.9       Debt   0.5 The CPRIT grant, together with Company match means the eRapa Phase 3 program is substantially funded. globenewswire.com - 1 month ago
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting May 22, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces a Notice of a General Meeting to be held at the Company's offices, 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ on 11 June 2025 at 1.00pm was posted to shareholders today. The Board of Directors is proposing four resolutions: Ordinary Resolutions       1. globenewswire.com - 2 months ago
Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M May 22, 2025 Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced its collaboration partner, Rapamycin Holdings, Inc. d/b/a Emtora Biosciences (“Emtora”) has been awarded an additional grant of $3.0 million from the Cancer Prevention & Research Institute of Texas (“CPRIT”). This award brings the total grant awarded by CPRIT to support the registrational Phase 3 program of eRapa in familial adenomatous polyposis (“FAP”) to $20.0 million. globenewswire.com - 2 months ago
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. zacks.com - 2 months ago
8. Profile Summary

Biodexa Pharmaceuticals Plc BDRX

image
COUNTRY GB
INDUSTRY Biotechnology
MARKET CAP $ 697
Dividend Yield 0.00%
Description Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Contact 1 Caspian Point, Cardiff, CF10 4DQ https://www.biodexapharma.com
IPO Date Dec. 7, 2015
Employees 13
Officers Mr. Stephen Anthony Stamp Chief Executive Officer, Chief Financial Officer, Company Secretary & Director Mr. Steve Ellul Chief Business Officer Dr. Gary A. Shangold CPI, FACOG, M.D. Chief Medical Officer Ms. Fiona Sharp Group Financial Controller Dr. Daniel Palmer MBA, Ph.D. Vice President of Technology